Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Radiotherapy for patients with acromegaly was considered when patients have residual disease or tumor recurrence after surgery, or when surgery can't be carried out. There are two main modes of radiotherapy, including stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT). We conducted a systematic review and meta-analysis to present the effectiveness and safety of SRS and FSRT for GH secreting pituitary adenoma in clinical practice. We searched the published literature using following databases: Pub Med, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and EMBASE up to March 22, 2020, for studies in which SRS or FSRT were used in patients with GH secreting pituitary. A total of 33 studies were eligible, involving 2016 participants. No significant differences were observed in tumor shrinkage rate, local tumor control rate and adverse effect rate between SRS and FSRT. Compared to FSRT, SRS showed significant increase in biochemical remission rate (43% vs. 28%; p=0.023) and significant lower follow-up GH level (SMD: -1.20 vs. -0.37, p=0.006). SRS and FSRT showed comparable effectiveness and safety in the management of GH secreting pituitary adenoma patients. SRS might be associated with better biochemical remission.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4158/EP-2020-0110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy With a Linear Accelerator (LINAC) for Acromegaly Remission: Clinical Experience From a Tertiary Neurological Center in Latin America.
Cureus
July 2025
Department of Neuroendocrinology, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Mexico City, MEX.
Background and objective Fractionated stereotactic radiotherapy (FSRT) and stereotactic radiosurgery (SRS) are commonly used in patients with growth hormone (GH)-secreting pituitary adenomas (PAs) who are not candidates for surgery, have residual disease postoperatively, or have failed or cannot access medical therapy. It is also considered a first-line option in elderly patients or those with comorbidities that contraindicate surgery. In this study, we aimed to evaluate the long-term outcomes of SRS and FSRT in patients with acromegaly who remained biochemically active despite prior surgical and/or medical treatment.
View Article and Find Full Text PDFPre-Operative Versus Post-Operative Fractionated Stereotactic Radiotherapy: A Single Institution Analysis of 534 Resected Metastases.
Int J Radiat Oncol Biol Phys
August 2025
Department of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address:
Background: Patients with large or symptomatic brain metastases typically have surgery followed by post-operative (post-op) stereotactic radiosurgery (SRS). However, post-op SRS leads to elevated rates of radiation necrosis (RN), nodular meningeal disease (nMD), and local failure (LF) when compared to whole brain radiotherapy. Fractionated stereotactic radiotherapy (FSRT) can deliver a higher biological effective dose and may reduce the risk of LF, and pre-operative (pre-op) treatments may reduce the risk of RN and nMD through treating smaller volumes and tumor sterilization.
View Article and Find Full Text PDFNon-invasive prediction of the secondary enucleation risk in uveal melanoma based on pretreatment CT and MRI prior to stereotactic radiotherapy.
Strahlenther Onkol
August 2025
Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.
Purpose: The aim of this study was to develop a radiomic model to non-invasively predict the risk of secondary enucleation (SE) in patients with uveal melanoma (UM) prior to stereotactic radiotherapy using pretreatment computed tomography (CT) and magnetic resonance (MR) images.
Materials And Methods: This retrospective study encompasses a cohort of 308 patients diagnosed with UM who underwent stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) using the CyberKnife system (Accuray, Sunnyvale, CA, USA) between 2007 and 2018. Each patient received comprehensive ophthalmologic evaluations, including assessment of visual acuity, anterior segment examination, fundus examination, and ultrasonography.
Volumetric and spatial changes in brain metastases during stereotactic radiosurgery: a case for off-line adaptive planning.
Clin Transl Radiat Oncol
September 2025
Anadolu Medical Center, Department of Radiation Oncology, Gebze, Kocaeli, Turkey.
Stereotactic radiosurgery is a widely used treatment modality for brain metastases, particularly in cases with a limited number and volume of lesions. While adaptive strategies have gained prominence in the stereotactic treatment of extracranial, their application in intracranial SRS remains largely unexplored. This case study presents a 45-year-old female with multiple brain metastases and significant perilesional edema, treated with fractionated stereotactic radiotherapy.
View Article and Find Full Text PDFFractionated stereotactic radiotherapy in people with drug-resistant focal epilepsy: first-in-human experience with a healthy tissue-preserving dose-fractionation concept.
Front Neurol
June 2025
Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Objective: Stereotactic radiosurgery (SRS) emerges as a non-surgical treatment option for drug-resistant non-neoplastic focal epilepsy. Previous studies have reported that in about 20% of patients treated with radiotherapy, however, subsequent salvage surgery is required, among other because of symptomatic radiation necrosis (RN). We propose a novel and radiobiologically substantiated dose-fractionation regimen which minimizes the RN risk while aiming to preserve efficacy and report our first-in-human experience.
View Article and Find Full Text PDF